For more than two decades, biopharma has struggled to develop safe and effective non-opioid pain therapies. With Vertex’s recent approval marking a long-awaited breakthrough, the momentum has reached a critical point for bringing non-opioid pain therapeutics to market.

Whether advancing NaV-targeting drugs or pursuing novel pain mechanisms, non-opioid therapeutics are now in the clinical spotlight and the next 12 months promise to be transformative.

The Non-Opioid Pain Therapeutics Summit provides a dedicated platform to harness that momentum. Attendees will be learning from companies with approvals such as Tonix, exploring late-stage strategies from innovators like Latigo and Algiax, and uncovering discovery breakthroughs from Nocion and Axonis. Join 70+ discovery, preclinical, translational and clinical industry-based experts driving the future of non-opioid pain therapies across diverse pain indications.